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Purpose: To evaluate visual field changes in patients with pituitary adenomas 
following trans-sphenoidal surgery. 
Methods: Eighteen patients with pituitary adenomas underwent a complete ophthalmic 
assessment and visual field analysis using the Humphrey Field Analyzer 30-2 program 
before and after trans-sphenoidal surgical resection at the Himalayan Institute of 
Medical Sciences over a one year period. Visual acuity, duration of symptoms, optic 
nerve head changes, pattern of visual field defects, and variables such as mean 
deviation and visual field index were compared.
Results: Thirty-six eyes of 18 patients including 10 male and 8 female subjects 
with mean age of 35.1±9.9 years and histologically proven pituitary adenoma were 
included. Mean visual acuity at presentation was 0.29 logMAR which improved 
to 0.21 logMAR postoperatively (P = 0.305). Of 36 eyes, 24 (66.7%) had visual field 
defects including temporal defects in 12 eyes (33.3%), non-specific defects in 10 eyes 
(27.8%), and peripheral field constriction in 2 eyes (5.6%). Mean deviation of visual 
fields at presentation was -14.28 dB which improved to -11.32 dB postoperatively. 
The visual field index improved from 63.5% to 75% postoperatively. Favorable visual 
field outcomes were correlated with shorter duration of symptoms and absence of 
optic nerve head changes at presentation.
Conclusion: Visual field defects were present in two thirds of patients at presentation. 
An overall improvement in vision and visual fields was noted after surgical resection. 
An inverse correlation was found between the duration of symptoms and postoperative 
visual field recovery, signifying the importance of early surgical intervention.
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INTRODuCTION
Pituitary adenomas are common lesions 
comprising 10 to 15% of all primary brain 
tumors.1 Incidental pituitary tumors are found in 
approximately 15% of autopsies.2 The majority of 
these lesions are histologically benign. Clinically, 
they present as functioning or non-functioning 
pituitary adenomas. Despite ongoing advances 
in the medical and radiotherapeutic management 
of pituitary tumors, surgical resection remains 
the therapy of choice for the vast majority of 
these lesions.3 Surgical resection is indicated in 
cases with progressive visual field deterioration. VFs in Pituitary Adenomas; Dhasmana et al
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Trans-sphenoidal surgery is performed when 
adequate resection is possible while sparing 
the normal gland.4
A spectrum of visual manifestations has 
been reported with these tumors, ranging from 
the absence of any visual symptoms to severe 
visual field defects and loss of vision. The 
prevalence of visual field defects in pituitary 
adenomas varies from 37 to 96% in different 
studies.5-7 The most common visual field defect 
is bitemporal hemianopia. However, other types 
of visual field deficits may also be observed.
The current study was undertaken to study 
visual outcomes of trans-sphenoidal resection 
in patients with pituitary adenomas at a single 
institute over a one-year period. 
METHODS
This prospective interventional study was 
conducted at the department of ophthalmology 
and neurosurgery of the Himalayan Institute 
of Medical Sciences, Swami Ram Nagar, 
Dehradun, from April 2009 to March 2010. 
The study was approved by the institutional 
review board/ethics committee. Patients with 
pituitary adenoma undergoing trans-sphenoidal 
surgical resection were included in the study, 
after providing written informed consent.
Inclusion Criteria
Patients over 10 years of age diagnosed with 
pituitary adenomas on radiological imaging.
Exclusion Criteria
1. Patients with ocular media opacities.
2. Patients with glaucoma, choroiditis, retinitis 
pigmentosa, optic neuritis, or any other 
ocular pathology affecting the visual field.
3. Patients physically and/or mentally unfit 
for detailed ocular examination.
4. Patients in whom visual field testing 
was not possible.
Outcome Measures
Each patient underwent a complete ocular 
examination including color vision and visual 
field assessment, preoperatively and one week 
and 3 months postoperatively. A detailed history 
was obtained and general physical examination 
was conducted for all patients. Visual field 
assessment was performed using the central 
30-2 program of the Humphrey automated 
static perimeter (720i, Carl Zeiss Meditec, Jena, 
Germany). Brain imaging studies including 
computed tomography (CT) or magnetic 
resonance imaging (MRI) were performed pre- 
and postoperatively in all patients.
Visual Field Protocol
Standard achromatic perimetry using the central 
30-2 program on the Humphrey Field Analyzer 
with Goldmann size III target was performed in 
all subjects pre- and postoperatively. Reliability 
criteria were fixation loss less than 20%, with 
false positive and false negative errors less 
than 33%.8
Changes in visual fields were analyzed 
separately for the right and left eyes in all 18 
patients (36 eyes). Mean deviation (in dB) was 
used to compare overall visual field changes 
using paired t-test. Categorical variables (patient 
age and duration of visual symptoms) were 
analyzed as potential predictive factors for 
recovery of visual field defects by the Kruskal 
Wallis H test, using SPSS software version 10 
(SPSS Inc., Chicago, IL, USA). Improvement in 
visual acuity was defined as a difference of at 
least 0.3 in logMAR notations.
RESuLTS
This series included 18 patients consisting of 10 
male and 8 female subjects with mean age of 
35.1±9.9 (range, 23 to 52) years and histologically 
proven pituitary adenomas. (Fig. 1). Visual 
acuity data are detailed in Table 1. Mean visual 
acuity was 0.29 logMAR at presentation and 
0.21 logMAR postoperatively (P = 0.81, Table 2).
Out of 36 studied eyes, 24 (66.7%) had 
visual field defects at presentation, including 
12 eyes (33.3%) with temporal defects, 10 
eyes (27.8%) with non-specific defects, and 2 
eyes with peripheral constriction (Fig. 2). The VFs in Pituitary Adenomas; Dhasmana et al
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most common pattern of visual field loss was 
bitemporal defects, present in 6 (33.3%) patients.
Visual field data were recorded pre- and 
postoperatively. Average visual field index at 
presentation was 63.5% which was significantly 
improved to 75% postoperatively (P = 0.004, 
Table 2). Mean deviation at presentation was 
-14.28 dB which also significantly improved 
to -11.32 dB postoperatively (P < 0.005). 
Overall, visual fields improved in 17 (47.2%) 
eyes and remained unchanged in 19 (52.8%) 
eyes. Improvement in mean deviation was not 
correlated with age.
Preoperative examination revealed 
unilateral optic atrophy in 3 patients, bilateral 
disc pallor in 2 patients, and normal optic disc 
appearance in 13 patients. Significant visual field 
improvement was observed in the subgroup of 
patients with no evident optic nerve changes 
(P < 0.001).
Relative afferent pupillary defect was 
present in 4 eyes at presentation which did not 
improve in any of the cases. Defective color 
vision (discriminating less than 12 of 14 Ishihara 
color plates) was noted in 15 (41.6%) eyes at the 
time of presentation. Postoperatively, 12 eyes 
(33.3%) had defective color vision (P = 0.10). 
Two patients presented with unilateral third 
nerve palsy, one of whom had complete third 
nerve palsy. 
Mean duration of symptoms was 5.8 months 
(range, 21 days to 1 year). The most common 
presentation was headache in 86.8% of patients. 
Five (13.9%) patients had visual symptoms. 
Duration of symptoms was less than 6 months in 
7 (38.9%) patients. Postoperative improvement 
in visual field was greater in this subset of 
patients, as compared to subjects with longer 
duration of symptoms (P < 0.001, Table 3).
DISCuSSION
Pituitary adenomas are generally slow-growing, 
benign neoplasms which can compress the 
anterior visual pathway, resulting in loss of 
vision. Anatomic relationships suggest that 
tumor extension 10 mm above the diaphragma 
sellae is necessary for the anterior visual 
pathway to become compressed. Trans-
Snellen visual acuity
Number of eyes
Preoperative Postoperative
>6/12 28 33
6/12 – 6/60 5 0
<6/60 3 3
Table 1. Distribution of eyes based on pre- and 
postoperative visual acuity
Visual parameters Pre-operatively Post-operatively
Mean Deviation (dB) 14.28 11.32
Visual Acuity (logMAR) 0.29 0.21
Visual Field Index 63.5% 75.0%
Table 2. Pre- and postoperative visual function 
parameters
Eyes Number of Eyes
VF 
Improved
VF not 
improved
Duration Less than 6 months 14 12 2
More than 6 months 22 5 17
Optic nerve 
profile
With disc changes 7 1 6
Without disc changes 29 16 13
Table 3. Postoperative visual field changes categorized 
by duration of symptoms and optic nerve head changes
Figure 1. Age and sex distribution of the study 
population.
Figure 2. Pre- and postoperative patterns of visual field 
defects.VFs in Pituitary Adenomas; Dhasmana et al
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sphenoidal surgical resection or craniotomy 
can decompress the anterior visual pathway, 
leading to visual recovery. Visual improvement 
occurs in three phases, with the earliest phase 
of improvement taking place one week after 
surgery.9 It has been postulated that the initial 
improvement in vision is the result of recovery of 
nerve conduction. Later improvement is thought 
to be due to remyelination of decompressed 
optic pathways.9 Trans-sphenoidal surgery 
is the surgical treatment of choice for most 
pituitary adenomas because it is minimally 
invasive and highly successful.7,10
In the present study, visual acuity better 
than 6/12 was present in 28 (77.8%) eyes. Five 
eyes (13.8%) had visual acuity worse than 6/60. 
Other studies have reported visual acuity better 
than 6/12 in 65 to 72% of cases and less than 
6/60 in 16.6 to 27.4% of eyes.10,11
At presentation, 12 (66.7%) patients had 
visual field changes while six did not. A range of 
visual field defects was noted; temporal defects 
were the most common abnormality, which is 
in accordance with existing literature.12 Non-
specific visual field changes were present in 6 
(27.8%) patients. Postoperatively, visual field 
defects improved and ultimately 18 eyes (50%) 
demonstrated normal fields. In other patients, 
the defects showed relative improvement after 
surgery. In another study, all cases had visual 
field defects with the most common being 
bitemporal defects noted in 50% of cases.11 
Non-specific field changes were reported in 20% 
of patients in another study.10 Peripheral field 
constriction has been reported in a comparable 
percentage of subjects.13
Optic nerve changes are common in 
patients with pituitary adenomas. Longstanding 
compression by pituitary macroadenoma leads 
to optic atrophy. Five (27.8%) patients in our 
series showed optic nerve head changes; 3 
patients had unilateral optic atrophy and 2 
patients had bilateral disc pallor. A previously 
published series reported optic nerve changes 
in 72% of cases.9 Similar to our findings, the 
latter study demonstrated normal optic nerve 
appearance to be predictive of visual field 
improvement.
Automated static perimetry is the gold 
standard for visual field evaluation. In the 
current study, visual field recovery was 
examined with static perimetry as it can provide 
quantitative assessment of the visual field and 
incorporate tests for patient reliability while 
adjusting for field changes due to age, cataract, 
and small pupils; furthermore it is also less 
prone to examiner bias.4
We observed a statistically significant 
increase in both mean deviation and visual 
field index. Postoperatively, improvement in 
mean deviation occurred in 16 (44.4%) eyes. 
Another study reported improvement in mean 
deviation in 61% of operated eyes.11 The visual 
field index is a new center-weighted indicator 
on automated perimetry and has been suggested 
to reflect retinal ganglion cell function.14 The 
visual field index serves as an improved measure 
of visual field loss graded from 0 to 100%, 
where 100% is a perfect visual field. Currently, 
literature is available on the use of this index 
in analyzing glaucoma progression. To our 
knowledge, no study has evaluated the effect 
of pituitary adenomas on the visual field index. 
In the current study we observed a statistically 
significant increase in the visual field index 
postoperatively suggesting an improvement 
in retinal ganglion cell function. Visual field 
improvement was positively correlated with 
duration of symptoms less than six months; 
a finding which has been reported in another 
series.10
Ocular presentations other than visual 
symptoms have been described in the literature 
for pituitary adenomas. In the current study, 
two patients presented with unilateral third 
nerve palsy. There was no improvement after 
surgery in one patient with complete third 
nerve palsy, while the other demonstrated 
some improvement. The prevalence of ocular 
motor palsy in patients with pituitary adenomas 
ranges from 1 to 14%.10,15 Various mechanisms 
have been proposed to explain involvement of 
the third cranial nerve; these include pressure 
transmitted to the cavernous sinus by a growing 
or invading tumor, and compression of the third 
nerve between the tumor and the interclinoid 
ligament.16 
Defective color vision has been reported in VFs in Pituitary Adenomas; Dhasmana et al
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56 to 71% of cases with sellar and suprasellar 
tumors.17,18 Mechanical compression of central 
or macular fibers by the tumor leads to loss of 
color vision.17 In the current study, color vision 
was affected in 41.6% of eyes which decreased 
to 33.3% of eyes postoperatively. All patients 
with color vision deficits had associated visual 
field defects. A recent study has suggested that 
recovery of visual field and visual acuity is 
more common than recovery of color vision.19 
The reason for this phenomenon is unclear. 
In summary, our series demonstrated that 
pituitary adenomas lead to visual field defects 
in 66.7% of patients. Trans-sphenoidal surgical 
resection resulted in an overall improvement 
in visual fields. Mean deviation and the visual 
field index also showed improvement after 
surgery. An inverse correlation was found 
between the duration of symptoms and 
postoperative visual field recovery, signifying 
the importance of early surgical intervention. 
There is a need for increasing awareness among 
the ophthalmic community and other physicians 
for timely referral of these patients and prompt 
neurosurgical intervention.
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